» Articles » PMID: 38863473

Demographic Profile and Etiology of Hepatocellular Carcinoma in Zaria, Northern Nigeria

Overview
Journal Niger Med J
Specialty General Medicine
Date 2024 Jun 12
PMID 38863473
Authors
Affiliations
Soon will be listed here.
Abstract

Background: HCC is a common cancer worldwide and one of the leading causes of cancer death. This aim of this study is to determine the age and gender characteristics of the HCC patients in our center and to determine the contribution of viral hepatitis (B and C) and alcohol to the etiology of HCC among our patients.

Methodology: This is a retrospective study of HCC patients seen at the gastroenterology unit of ABUTH between April 2015 and September 2018. Data on age, gender, HBsAg, and HCV antibody status and alcohol consumption were recorded from the case files of all eligible patients.

Results: A total of 87 patients were included in the study. They consisted of 68 males (78.2%) and 19 females (21.8%) with male to female ratio of 4:1. The mean age of the study subjects was 46.7 years (SD ± 12.5), with a range of 22 and maximum age of 80 years. Majority of the patients were within the age group 40-49 (32.2%). HBsAg was present in 48 patients (55.2%), HCV antibody was positive in 14 patients (16.1%) and 3 patients (3.4%) were positive for both HBsAg and HCV antibody. Four (4.6%) had significant alcohol ingestion and in 18 patients (20.7%), the etiology was undetermined.

Conclusion: In our study, HCC was found predominantly among male patients in the age group 40-49 years. Viral hepatitis particularly HBV is the most important etiological factor for HCC among our patients.

Citing Articles

Liver cell cancer surveillance practice in Nigeria: Pitfalls and future prospects.

Musa Y, Ifeorah I, Maiyaki A, Almustapha R, Maisuna Y, Saleh H World J Hepatol. 2024; 16(10):1132-1141.

PMID: 39474579 PMC: 11514613. DOI: 10.4254/wjh.v16.i10.1132.

References
1.
Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J . The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004; 39(1):211-9. DOI: 10.1002/hep.20027. View

2.
Sumida Y, Yoneda M . Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2017; 53(3):362-376. PMC: 5847174. DOI: 10.1007/s00535-017-1415-1. View

3.
Sartorius K, Sartorius B, Aldous C, Govender P, Madiba T . Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 2015; 39(3):284-90. DOI: 10.1016/j.canep.2015.04.006. View

4.
Fakunle Y, Ajdukiewicz A, Greenwood B, EDINGTON G . Primary liver cell carcinoma (PLCC) in the Northern Guinea Savanna of Nigeria. Trans R Soc Trop Med Hyg. 1977; 71(4):335-7. DOI: 10.1016/0035-9203(77)90114-6. View

5.
Liu C, Kao J . Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 2007; 70(4):141-5. DOI: 10.1016/S1726-4901(09)70346-6. View